Pierre Fabre
New ways to care  

This September 24th, we come together for Metastatic Colorectal Cancer (mCRC) World Day. This day is an important time for patients, families, and healthcare professionals to share information, raise awareness, and support. This day serves as a collective call to action, to expand our understanding of mCRC and highlight the importance of early detection, personalized treatment, and ongoing support for those living with mCRC. By understanding the unique features of each person's cancer, especially tumor biomarkers, we can open the door to more personalized therapies, and possibly, to greater hope. Raising awareness about metastatic colorectal cancer and encouraging proactive conversations about testing, treatment options, and support resources are crucial steps in improving outcomes and quality of life. Together, we can foster a community where no one faces this diagnosis alone, and where access to information leads to informed choices and better care for all.

Pierre Fabre Laboratories celebrated the 20th anniversary of its employee shareholding plan, in the presence of Patrick Martin, Chairman of the MEDEF, Jean-Claude Mailly, former General Secretary of Force Ouvrière, and Olivier Paon, Chairman of the Fédération de l'Actionnariat Salarié (FAS).

Castres, 19 September 2025 - On the occasion of the EADV (European Academy of Dermatology and Venereology) Congress, taking place from September 17 to 20, 2025 in Paris, dermatologists around the world will be able to discover the new quality of life, PRIDD™ (Patient-Reported Impact of Dermatological Diseases) in a clinical study supported by Eau Thermale Avène brand. 

Join us in recognizing World Lymphoma Awareness Day, 15th September, a day dedicated to raising awareness of lymphomas, which are cancers of the lymphocytes or white blood cells.    This day sheds light on a type of cancer with more than 80 subtypes and that affects up to 864,000 people world wide1,2. One of these subtypes is Post-Transplant Lymphoproliferative disorder (PTLD).   PLTD is a rare disease characterized by the development of lymphoid neoplasms after solid organ or hematopoietic stem cell transplantation3,4.    As we mark World Lymphoma Awareness Day this September, Pierre Fabre Laboratories is dedicated to shine a light on this rare condition. PTLD is a potentially life-threatening complication that can occur after an organ transplant. The occurrence of PTLD varies from 2% to 20%, depending on the type of transplant5.   Our commitment is to educate, support, and inspire action among patients, healthcare professionals, and the broader community to improve understanding and management of PTLD.  

Toulouse, June 20, 2025 - Pierre Fabre Laboratories announces the appointment of Audrey Ricard Campion as Head of Research and Development for its Dermo-Cosmetics & Personal Care business. Reporting to Frédéric Ennabli, CEO of Pierre Fabre Dermo-Cosmetics, she will join the Executive Committee and will be responsible for defining and implementing the company’s innovation strategy. An engineering graduate in physics and chemistry, Audrey Ricard Campion has acquired in-depth expertise in the science of skin over the course of her career. Her work, characterized by the encapsulation and vectorization of active ingredients and pigments, as well as the use of adhesive polymers, has given rise to numerous patents, particularly in the fields of photoprotection and facial skincare. Audrey will now be putting her experience to work for Pierre Fabre Laboratories' Dermo-Cosmetics & Personal Care portfolio, which includes major international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer and Elgydium. Audrey Ricard Campion will be based at the Pierre Fabre Innovation Center, on the Oncopole campus in Toulouse. She will head up an organization of 420 employees based mainly in Toulouse, as well as in the innovation centers in Shanghai, specializing in Asian skin types, and Rio de Janeiro, specializing in skin types found in South America.  She will be able to draw on multidisciplinary expertise, including biology, clinical pharmacology, biotechnology and formulation, to support priority fields of research such as sun protection, acne treatment, atopy, skin repair and alopecia.

SECAUCUS, NJ (June 18, 2025): Pierre Fabre Laboratories, a global healthcare company originated from France, announces the inauguration of its new US office located on 500 Plaza Drive, in Secaucus, NJ which will host its dermo-cosmetics and medical care subsidiaries. Pierre Fabre is the world’s second-largest dermo-cosmetics manufacturer and a global player in oncology, cell & gene therapy, rare disease and dermatology. This strategic move in the US marks a pivotal moment in the company’s growth strategy, underscoring its strong commitment to advancing in the US in both dermo-cosmetics and medical care. Pierre Fabre Laboratories introduced global dermo-cosmetics brands Avène, Klorane and René Furterer to the US market in the 1990’s. With an ever-growing desire for French dermo-cosmetics, the US dermo-cosmetics business has become a top priority. Building upon their success in oncology and dermatology in Europe and Asia, the company has recently expanded its medical care investments in the US through the creation of a dedicated pharmaceutics unit, Pierre Fabre Pharmaceuticals (PFP). This subsidiary is focused on continuing to deliver breakthrough therapies in rare diseases and oncology to American patient populations with high unmet needs and limited treatment options.

PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC")

Find the 2025 annual report (2024 figures) online. We have placed this year’s annual report under the sign of a “new energy” resulting in :  International growth Therapeutic innovations Medical leadership Financial solidity Collective commitment